MedPath

ALT-801

Generic Name
ALT-801
Drug Type
Biotech
CAS Number
1188450-53-4
Unique Ingredient Identifier
QWZ40O5W6K
Background

ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).

Clinical Trials
Related News

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Phase 2
Completed
Conditions
Obesity/Overweight
Interventions
Other: Placebo
First Posted Date
2022-03-25
Last Posted Date
2023-11-29
Lead Sponsor
Altimmune, Inc.
Target Recruit Count
391
Registration Number
NCT05295875
Locations
🇺🇸

Altimmune CTM, Saint George, Utah, United States

🇺🇸

National Research Institute, Los Angeles, California, United States

🇺🇸

Cornell University, Joan and Sanford Weill Medical College, New York, New York, United States

and more 1 locations

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Phase 1
Completed
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Other: Placebo
First Posted Date
2022-03-23
Last Posted Date
2023-07-27
Lead Sponsor
Altimmune, Inc.
Target Recruit Count
64
Registration Number
NCT05292911
Locations
🇺🇸

Wake Research CRCN, Las Vegas, Nevada, United States

🇺🇸

Panax Clinical Research, Miami Lakes, Florida, United States

🇺🇸

Diagnostics Research Group, San Antonio, Texas, United States

and more 8 locations

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

Phase 1
Completed
Conditions
Type 2 Diabetes
Interventions
Other: Placebo
First Posted Date
2021-11-26
Last Posted Date
2023-08-14
Lead Sponsor
Altimmune, Inc.
Target Recruit Count
55
Registration Number
NCT05134662
Locations
🇺🇸

Altimmune CTM, Tomball, Texas, United States

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Phase 1
Completed
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Other: Placebo
First Posted Date
2021-08-16
Last Posted Date
2023-07-27
Lead Sponsor
Altimmune, Inc.
Target Recruit Count
95
Registration Number
NCT05006885
Locations
🇺🇸

Panax Clinical Research, Miami Lakes, Florida, United States

🇺🇸

Pinnacle Research, San Antonio, Texas, United States

🇺🇸

Diagnostics Research Group, San Antonio, Texas, United States

and more 10 locations

ALT-801 DDI Study in Healthy Volunteers

First Posted Date
2021-07-22
Last Posted Date
2022-12-08
Lead Sponsor
Altimmune, Inc.
Target Recruit Count
40
Registration Number
NCT04972396
Locations
🇦🇺

Q-Pharm, Herston, Queensland, Australia

🇦🇺

CMAX Clinical Research, Adelaide, South Australia, Australia

ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

Phase 1
Completed
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Other: Placebo
First Posted Date
2020-09-23
Last Posted Date
2021-11-10
Lead Sponsor
Altimmune, Inc.
Target Recruit Count
100
Registration Number
NCT04561245
Locations
🇦🇺

Nucleus Networks, Herston, Queensland, Australia

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy